Introduction
============

Bullous pemphigoid (BP) is the most common autoimmune bullous disease affecting the skin and mucosal membranes, with antibodies directed against the 180-kDa BP antigen (BP180) and the 230-kDa BP antigen (BP230) located in the basement membrane zone ([@b1-etm-0-0-7057]). BP commonly affects older patients and females are slightly more affected than males ([@b2-etm-0-0-7057]).

Up to 20% of the patients with classical BP may have at the onset of the disease a non-bullous phase of variable duration with non-specific itchy lesions (eczematous patches, urticarial plaques, polycyclic, targetoid, nodular, lichenoid or vesicular lesions) ([@b3-etm-0-0-7057]).

Pemphigoid nodularis (PN) is a rare variant of BP having clinical features of prurigo nodularis with an autoantibody profile of BP ([@b4-etm-0-0-7057]). Hyperkeratotic, excoriated and pruritic nodules on the extremities can be the first sign of PN anticipating the blisters by weeks or months. In some cases the blisters cannot be observed through-out the whole course of the disease making diagnosis substantially difficult ([@b3-etm-0-0-7057]). The pathogenesis of PN is not well understood. Skin physical trauma like persistent scratching exposes hidden antigens of the basal membrane to the immune system, leading to the production of autoantibodies in predisposed individuals ([@b5-etm-0-0-7057]).

The aim of the study is to present a case of PN and a systematic review of the published PN cases regarding clinical aspects, histopathological features, laboratory findings and treatment options.

Case report
===========

Caucasian, 81-year female, with a history of ischemic heart disease, chronic obstructive pulmonary disease and bilateral gonarthrosis was admitted in to the hospital in July 2016 for a nodular-excoriated eruption on her trunk and extremities with abrupt onset, \~2 months before admission. Clinical examination revealed violaceous, highly pruritic nodular lesions, some with excoriations, other with a pale and atrophic center ([Fig. 1](#f1-etm-0-0-7057){ref-type="fig"}). Most lesions presented a hyperpigmented, bluish halo. The lesions were located on the trunk and limbs, with sparing of the face and interscapular region. All the skin was dry and scaly. The emotional and psychosocial background was stable. Complete blood count, liver and kidney function were normal. Thyroid function was normal, but levels of thyroid peroxidase and antithyroglobulin antibodies were increased. IgE level in the blood was elevated (2002.9 UI/ml; normal \<100.0 UI/ml). The first skin biopsy showed marked hyperkeratosis, focal parakeratosis, and mild spongiosis; the dermis had marked mixed inflammatory infiltrate (lymphocytes, plasmacytes, neutrophils, eosinophils) with a diffuse and perivascular pattern. PAS stain showed no mycotic colonies ([Fig. 2](#f2-etm-0-0-7057){ref-type="fig"}). Direct immunofluorescence (DIF) performed from the margin of the same lesion was negative; ELISA for BP180 and BP230 were also negative. Screening for an underlying malignancy was negative.

At this point, she was diagnosed with prurigo nodularis, atopy, autoimmune thyroiditis and xerosis cutis. In order to interrupt the cycle of itching-scratching a treatment with topical corticosteroids and calcipotriol for 6 weeks was started, with no improvement.

After 2 months urticarial plaques appeared with no evidence of blister formation ([Fig. 3](#f3-etm-0-0-7057){ref-type="fig"}). A new skin biopsy was performed from these new lesions showing hyperkeratosis, focal parakeratosis, spongiosis, subepidermal bulla and a lymphoplasmacytic and neutrophilic infiltrate with diffuse and perivascular pattern ([Fig. 4](#f4-etm-0-0-7057){ref-type="fig"}).

DIF revealed linear C3 deposits along the basal membrane ([Fig. 5](#f5-etm-0-0-7057){ref-type="fig"}). ELISA from serum was positive for BP230 antibody (79.0 U/ml, normal \<20.0 U/ml) and was negative for BP180. The clinical and histologic aspect, together with C3 linear distribution at the basal membrane and positivity of BP230 antibodies were consistent with the rare diagnosis of pemphigoid nodularis. She started a treatment with prednisone (0.5 mg/kg/day) for 2 weeks which was gradually tapered by 5 mg/week in the following 6 weeks. Topical therapy consisted in one application of clobetasol propionate 0.05% in the evening. The pruritus, nodules and urticaria-like eruption remitted under corticotherapy. In order to minimize the risk of adverse reactions and thus to discontinue the treatment with systemic corticosteroids, we introduced fexofenadine hydrochloride (240 mg/day), montelukast sodium (10 mg/day) and continued topical applications of clobetasol propionate. After 3 months, the nodular lesions were improved, without any sign of recurrence.

Unfortunately, 2 weeks after the last visit the patient died due to a hemorrhagic stroke, which, in our opinion, was unrelated to the autoimmune bullous disease.

Materials and methods
=====================

We conducted a literature search in English and French of the MEDLINE database on 18th May 2018 using the following terms: 'nodular pemphigoid', 'pemphigoid nodularis', 'pemphigoid' and 'nodularis', without limitations on article type and restricted the papers to those published in English or French. We collected data on: age at diagnosis, sex, origin, associated diseases, duration of symptoms before diagnosis, clinical presentation, results of diagnostic tests, treatment options and outcome.

The study was approved by the Ethics Committee of the Emergency County Hospital (Cluj-Napoca, Romania), and written informed consent was provided by the patient for this study.

We defined PN patients as patients who presented with a pruritic papulo-nodular eruption followed by a positive analysis of either DIF, indirect immunofluorescence (IIF) or immunoserology. Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) software. Data were presented as mean ± SD.

A total of 51 articles were found. We excluded from our review: three articles because of language limitations, 6 articles due to incomplete data and 6 articles were not relevant to the question.

A total of 36 articles included in the study presented 47 cases of PN between 1981 and 2018 ([Table I](#tI-etm-0-0-7057){ref-type="table"}). All the characteristics of the cases reported are summarized in [Tables II](#tII-etm-0-0-7057){ref-type="table"}--[V](#tV-etm-0-0-7057){ref-type="table"}.

The female to male ratio was 1.8:1. The mean age of onset was 66.2 years, SD ± 12.3, median age 70 (for patients aged 41--91 years) and 13.3 years, SD ± 2.1, median age 14 (for patients aged 11--15 years). Most of the patients were non-Caucasian \[49.0%, 23 patients (pts)\], 12 pts were Caucasian (25.5%) while for 12 pts the origin was not mentioned. As comorbidities, we found autoimmune diseases (rheumatoid arthritis, ulcerative colitis, autoimmune thyroiditis, IPEX, bullous pemphigoid, dermatitis herpetiformis, idiopathic chronic eosinophilic pneumonia) in 16 pts (34.0%), inflammatory diseases (psoriasis) in 1 pts (2.1%), allergic diseases (asthma and atopic diathesis) in 2 pts (4.2%) and diabetes mellitus in 3 pts (6.4%) ([Table II](#tII-etm-0-0-7057){ref-type="table"}).

For all patients the primary lesions were considered as pruritic, hyperkeratotic or excoriated papules and/or nodules, on the extremities and trunk, and 46.8% (22 pts) developed secondary lesions (blisters, vesicles, urticarial plaques) before or after the diagnosis of PN has been established. One case had oral mucosa involvement. Data concerning the duration of the disease (after onset of initial lesions) was found in 35 out of 47 pts (for 7 pts data was not recorded, and 5 pts had prior blistering autoimmune disease). Mean duration was 23.6 months, SD ± 31.9, with the median value of 9 months. Histopathological examination from a hyperkeratotic nodule was performed in 37 pts (78.7%); spongiosis and/or subepidermal cleft was noted in 13 pts (35.1%), which are not suggestive for prurigo nodularis, and dermal eosinophils in 23 pts (62.2%), while one patient presented non-specific features. High serum total IgE levels were found in 13 pts (27.7%) and eosinophilia in 5 pts (10.6%) ([Table III](#tIII-etm-0-0-7057){ref-type="table"}).

Diagnosis was confirmed by immunofluorescence analysis (DIF: linear deposits of IgG and/or C3 along the basement membrane zone, IIF on monkey esophagus or 1M salt-split normal human skin: linear deposit of IgG with epidermal binding \>1:80) and circulating autoantibody tests. Of 47 cases, DIF from pruritic papule and/or nodule was carried out in 30 pts and was positive in 26 pts (86.7%). All 21 pts that developed secondary lesions presented positive perilesional DIF (100%).

IIF was performed in 39 pts and was positive in 36 (92.3%). Immunoblot (western blotting) analysis was performed for 19 pts; it was positive in all cases: 4 pts for 180 kDa (21.1%), 11 pts (57.9%) for 230 kDa (220 kDa) and 4 pts (21.1%) for both. Nineteen patients were analyzed by ELISA and positive tests were found in all patients; for BP180 in 12 pts (63.1%), for BP230 in 1 pts (5.3%) and for both (BP180+BP230) in 6 pts (31.6%) ([Table IV](#tIV-etm-0-0-7057){ref-type="table"}).

Post-therapeutic clinical outcome of reported cases was evaluated as 'good' (significant improvement of pruritus, gradual resolution of skin lesions), 'partial' (persistence of some skin lesions) and 'no response'. We summarized available data as the name of drugs, dosage (minimal and maximal), and duration of administration in [Table V](#tV-etm-0-0-7057){ref-type="table"}. We found that the best therapeutic options were systemic and topical corticosteroids.

Discussion
==========

Our systematic review summarized the reported characteristics of PN, a rare variant of BP having clinical features of prurigo nodularis with an autoantibody profile of BP. The features of the present case report are similar to the ones reported in the literature, highlighting the elderly patient group, presenting initial papulo-nodular pruritic lesions and secondary vesicular/ bullous lesions or urticarial plaques. This atypical onset of PN partially explains the diagnosis delay, especially in the absence of obvious clinical signs of BP. We consider that clinicians should take into consideration DIF microscopy in elderly patients with pruritic papulo-nodular eruption.

As for the pediatric patients, autoimmune blistering diseases are rare and their prevalence unclear. Interestingly, in the few cases of PN reported in children, most of them had previous long-standing BP, suggesting a hyperproliferative integrin profile ([@b6-etm-0-0-7057]).

Mucosal involvement was reported in 10--30% of patients with BP ([@b7-etm-0-0-7057]). Our review shows a lower incidence of 2.1%, suggesting that oral mucosa involvement is less frequent in PN.

Drug-induced disease due to various medication (antibiotics, NSAID, diuretics, anti-TNF-α, antidiabetics, antiarrhythmics and antihypertensives) was reported in some cases of BP ([@b8-etm-0-0-7057]). We found only one patient who was treated for rheumatoid arthritis with etanercept (anti-TNF-α drug) before the onset of PN, which imposed a discontinuation of the drug with favorable effect ([@b9-etm-0-0-7057]).

Histopathologic findings in PN show features of prurigo nodularis (orthohyperkeratosis, focal parakeratosis and irregular epidermal hyperplasia) ([@b10-etm-0-0-7057]) and bullous pemphigoid (eosinophilic spongiosis more than 50% and a subepidermal cleft 80%) ([@b11-etm-0-0-7057]). Skin nodule biopsies revealed spongiosis and/or subepidermal split in some cases but, more frequently, dermal eosinophilic infiltrate, indicating the necessity of performing DIF microscopy and immunoserology assays in addition to the histopathological examination.

DIF and IIF on salt-split skin microscopy have high specificity, 98 and 100%, respectively ([@b12-etm-0-0-7057]) in BP and they are the most reported positive diagnostic tests in nonbullous pemphigoid, 93.2 and 90.2%, respectively ([@b1-etm-0-0-7057]). In the PN cases that were reported, DIF microscopy performed from nodular lesions was positive in most cases, while it was positive in all patients when secondary lesions were clinically obvious. IIF was positive similar to the previously reported data. As a result, a negative DIF does not exclude PN.

The diagnosis must be completed with immunoserology testing as ELISA or Immunoblot (western blotting). Since 2002 most reported cases of PN were confirmed by ELISA and we found that all were positive, either for BP180, BP230 or both. Moreover, ELISA testing can be useful in follow-up, the levels of BP antibodies decreasing as the clinical aspect improves under treatment.

A recent study indicated that BP patients can have pathologic peripheral eosinophilia (50.2%) ([@b13-etm-0-0-7057]). This finding was significantly correlated with the age of patients (older patients) and the severity of the palmoplantar involvement. Moreover, peripheral eosinophil count is significantly correlated with levels of both anti-BP180 IgG and IgE ([@b14-etm-0-0-7057]). The association between serum eosinophilia and BP or PN is still unclear as Kridin found no correlation between atypical clinical variants of BP (prurigo-like type) and serum eosinophilia ([@b13-etm-0-0-7057]), while our data revealed serum eosinophilia in some patients, who also had high levels of serum total IgE and anti-BP180 IgG antibody. Eosinophils play an important role in the pathogenetic cascade of BP and PN as well as in other autoimmune diseases ([@b15-etm-0-0-7057],[@b16-etm-0-0-7057]).

Elevated IgE levels were reported in 70% of patients with BP in 1974 ([@b17-etm-0-0-7057]). It was also shown that IgE abnormalities and impaired B lymphocyte function is correlated with serum levels of soluble CD23 ([@b18-etm-0-0-7057]). Although in the review of Saniklidou *et al* on bullous pemphigoid no correlations were found between IgE levels and the nodular form of the disease ([@b19-etm-0-0-7057]), our data showed high levels serum total IgE in 13 patients (27.7%). Ten out of the later thirteen patients had positive DIF performed from nodular lesions, positive IIF and tissue eosinophilia.

Although literature data did not find an increased risk for autoimmune disorders in patients with BP ([@b20-etm-0-0-7057]), we found one third of patients having this association. These findings could be explained by a genetic susceptibility to develop autoimmune diseases.

Treatment in PN remains difficult and challenging as the condition is chronic, severely pruritic, occurring in elderly patients with multiple comorbidities. Due to adverse effects of immunosuppressive medication there is a need to find therapeutic alternatives. Reported data regarding treatment are incomplete, lacking details such as dosage, duration of administration.

The best therapeutic results were obtained using systemic corticosteroids, azathioprine, dapsone, intravenous Ig, minocycline. However, topical and systemic corticosteroids continue to remain the gold standard in PN. Our review shows that the therapeutic response is directly correlated with the dose and the treatment duration.

In our case, after a significant improvement of the pruritus and the aspect of the nodules under corticosteroid treatment, we chose to continue due to comorbidities, with a combination of montelukast sodium (leukotriene receptor inhibitor) and fexofenadine hydrochloride (second generation antihistamine antagonist) ([@b21-etm-0-0-7057]). Unfortunately, we could not evaluate the therapeutic outcome on the long-term, due to the death of the patient, which we believe was unrelated to PN.

Our review has a few limitations. The first is that the results are based on case reports and small case series. Moreover, data regarding the treatment is inconsistent in most of the published articles. As strength, our review offers a clear overview concerning the most important aspects of PN in cases reported so far.

In conclusion, PN should be recognized as a rare form of bullous pemphigoid and must be taken into consideration as a differential diagnosis of pruritic papulo-nodular eruption in the elderly. Refractory, chronic and unexplained pruritus in those patients should lead to skin biopsy and DIF/IIF microscopy as well as immunoserology analysis to detect PN.
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![Primary lesions - multiple hyperkeratotic nodules, postinflammatory hyper/hypopigmentation, multiple excoriations.](etm-17-02-1132-g00){#f1-etm-0-0-7057}

![Histopathological exam showing marked hyperkeratosis, focal parakeratosis, and mild spongiosis, mixed inflammatory infiltrate (lymphocytes, plasmacytes, neutrophils, eosinophils) with a diffuse and perivascular pattern in the dermis; magnification, ×10; haematoxylin and eosin staining.](etm-17-02-1132-g01){#f2-etm-0-0-7057}

![Secondary lesions - urticarial plaques with postbullous erosions on the surface and excoriations on the forearm.](etm-17-02-1132-g02){#f3-etm-0-0-7057}

![Histopathological exam showing hyperkeratosis, focal parakeratosis, spongiosis, subepidermal bulla and a lymphoplasmacytic and neutrophilic infiltrate with diffuse and perivascular pattern; magnification, ×10; haematoxylin and eosin staining.](etm-17-02-1132-g03){#f4-etm-0-0-7057}

![DIF microscopy - linear deposit of C3 along the basement membrane zone.](etm-17-02-1132-g04){#f5-etm-0-0-7057}

###### 

All included articles and cases reported.

  Author (refs.)                                 No. of cases reported   Publication year
  ---------------------------------------------- ----------------------- ------------------
  36 articles                                    47 cases                1981--2018
  Yoneda *et al* ([@b22-etm-0-0-7057])           1                       2018
  Zhang *et al* ([@b23-etm-0-0-7057])            1                       2017
  Amber *et al* ([@b4-etm-0-0-7057])             1                       2017
  Yoshimoto *et al* ([@b24-etm-0-0-7057])        1                       2017
  Dangel *et al* ([@b25-etm-0-0-7057])           1                       2016
  Asahina *et al* ([@b15-etm-0-0-7057])          1                       2015
  Kwong and Lim ([@b26-etm-0-0-7057])            1                       2015
  Al-Salhi and Alharithy ([@b27-etm-0-0-7057])   1                       2015
  Das and Bandyopadhyay ([@b28-etm-0-0-7057])    1                       2014
  Mochizuki *et al* ([@b9-etm-0-0-7057])         1                       2013
  Matsudate *et al* ([@b29-etm-0-0-7057])        2                       2009
  Koga *et al* ([@b30-etm-0-0-7057])             1                       2009
  Aboumaria *et al* ([@b31-etm-0-0-7057])        1                       2008
  Teraki and Fukuda ([@b32-etm-0-0-7057])        1                       2008
  McGinnes *et al* ([@b16-etm-0-0-7057])         1                       2006
  Gach *et al* ([@b33-etm-0-0-7057])             2                       2005
  Tashiro *et al* ([@b34-etm-0-0-7057])          2                       2005
  Sakuma-Oyama *et al* ([@b35-etm-0-0-7057])     1                       2003
  Powell *et al* ([@b5-etm-0-0-7057])            5                       2002
  Schachter *et al* ([@b6-etm-0-0-7057])         1                       2001
  Gao *et al* ([@b36-etm-0-0-7057])              1                       2001
  Ameen *et al* ([@b37-etm-0-0-7057])            1                       2000
  Cliff and Golden ([@b38-etm-0-0-7057])         3                       1997
  Kossard ([@b39-etm-0-0-7057])                  1                       1996
  Tamada *et al* ([@b40-etm-0-0-7057])           1                       1995
  Bourke *et al* ([@b41-etm-0-0-7057])           1                       1994
  Ratnavel *et al* ([@b42-etm-0-0-7057])         1                       1994
  Gallo *et al* ([@b43-etm-0-0-7057])            1                       1993
  Borradori *et al* ([@b44-etm-0-0-7057])        1                       1992
  Ross *et al* ([@b45-etm-0-0-7057])             3                       1992
  Borradori *et al* ([@b46-etm-0-0-7057])        1                       1990
  Tani *et al* ([@b47-etm-0-0-7057])             1                       1989
  Shimizu *et al* ([@b48-etm-0-0-7057])          1                       1988
  Roenigk and Dahl ([@b49-etm-0-0-7057])         1                       1986
  Massa and Connolly ([@b50-etm-0-0-7057])       1                       1982
  Yung *et al* ([@b51-etm-0-0-7057])             1                       1981

###### 

Demographic and personal history characteristics.

  Data                     \% (no. of pts)
  ------------------------ -----------------------------
  Sex                      
    Male                   36.2 ([@b17-etm-0-0-7057])
    Female                 63.8
    Female:Male ratio      1.8:1 ([@b30-etm-0-0-7057])
  Age (years; mean ± SD)   
    11--15 (3 pts)         13.3±2.1; 14 years
    41--91 (44 pts)        66.2±12.3; 70 years
  Origin                   
    Caucasian              25.5 ([@b12-etm-0-0-7057])
    Non-Caucasian          49.0 ([@b23-etm-0-0-7057])
    Not mentioned          25.5 ([@b12-etm-0-0-7057])
  Associated diseases      
    Autoimmune             34.0 ([@b16-etm-0-0-7057])
    Allergic               4.2 ([@b2-etm-0-0-7057])
    Inflammatory           2.1 ([@b1-etm-0-0-7057])
    Diabetes mellitus      6.4 ([@b3-etm-0-0-7057])

No. of pts, number of reported patients.

###### 

Clinical, histopathological and blood tests findings.

  Data                                                                   \% (no. of pts)
  ---------------------------------------------------------------------- -----------------------------
  Clinical aspect                                                        
  Primary lesions^[a](#tfn2-etm-0-0-7057){ref-type="table-fn"}^ and/or   100 ([@b47-etm-0-0-7057])
    secondary lesions^[b](#tfn3-etm-0-0-7057){ref-type="table-fn"}^      46.8 ([@b22-etm-0-0-7057])
  Duration of symptoms before diagnosis (months)                         
    Mean ± SD, 23.6±31.9 (range 1--132)                                  74.5 ([@b35-etm-0-0-7057])
    Median 9                                                             
  Histopathology, from a nodular lesion                                  78.7% ([@b37-etm-0-0-7057])
    Spongiosis and/or cleft                                              35.1 ([@b13-etm-0-0-7057])
    Eosinophilic infiltrate                                              62.2 ([@b23-etm-0-0-7057])
  Blood tests                                                            
    Eosinophilia                                                         10.6 ([@b5-etm-0-0-7057])
    High value of total IgE                                              27.7 ([@b13-etm-0-0-7057])

Primary lesions: pruritic papules and/or nodules

secondary lesions: urticarial plaques, vesicles, tense bullae. No. of pts, number of reported patients.

###### 

Characteristics of immunofluorescence microscopy and immunoserologic tests.

  Immunologic tests                                                                        Positive (%)   Negative (%)   No. of pts
  ---------------------------------------------------------------------------------------- -------------- -------------- ------------
  DIF, pruritic papule and/or nodule                                                       26/30 (86.7)   4/30 (13.3)    46
  DIF, once the secondary lesions appeared^[a](#tfn4-etm-0-0-7057){ref-type="table-fn"}^   21/21 (100)    0              
  IIF (monkey esophagus/salt-split skin)                                                   36/39 (92.3)   3/39 (7.9)     39
  Immunoblot 180 kDa                                                                       4/19 (21.1)    --             19
  Immunoblot 230 kDa                                                                       11/19 (57.9)   --             
  Immunoblot 180 kDa and 230 kDa                                                           4/19 (21.1)    --             
  ELISA BP180                                                                              12/19 (63.1)   --             19
  ELISA BP230                                                                              1/19 (5.3)     --             
  ELISA BP180 and BP230                                                                    6/19 (31.6)    --             

Perilesional; no. pts, number of reported cases; DIF, direct immunofluorescence; IIF, indirect immunofluorescence.

###### 

Treatment of reported cases.

                                                                                   Clinical outcome (no. of pts)       
  ---------------------------- -------------------- --------------- -------------- ------------------------------- --- ---
  Topical corticosteroids      --                   --              18 weeks       4                               1   4
  Prednisone                   1 mg/kg/day          0.5 mg/kg/day   6--10 months   9                               1   0
  Prednisolone                 1 mg/kg/day          0.1 mg/kg/day   3 months       7                               9   1
  Betamethasone                20 mg/day            0.5 mg/day      NM             2                               0   0
  Methylprednisolone           0.4 mg/kg            0.2 mg/kg       \>6 months     1                               0   0
  Azathioprine                 50 mg tid            50 mg/day       12 months      7                               1   0
  Dapsone                      100 mg/day           50 mg/day       NM             3                               1   0
  IVIg                         2 g/kg/day, 5 days   --              10 months      2                               1   0
  Minocycline                  100 mg bid           100 mg/day      NM             2                               1   2
  Mycophenolate mofetil        2 g/day              1.5 g/day       NM             1                               1   0
  Sulfamethoxyi-pyridazine     500 mg tid           500 mg/day      2--4 years     1                               1   0
  Fexofenadine + Montelukast   240 mg bid +10 mg    --              4 weeks        1                               1   1
  Niacinamide                  500 mg tid           --              6 months       1                               0   2
  Suplataste tosilate          300 mg/day           --              NM             1                               0   0
  Rituximab                    375 mg/mp            --              NM             1                               0   0
  Triamcinolone i.m.           60 mg                --              NM             0                               1   0
  Cyclosporine                 NM                   NM              NM             0                               1   0
  Methotrexate                 15 mg/week           NM              3 months       0                               0   1
  Cyclophosphamide             NM                   NM              NM             0                               0   1
  Oral Antihistamines          NM                   NM              NM             0                               0   6

NM, not mentioned; good, significant improvement of pruritus, gradual resolution of the skin lesions; partial, persistence of some skin lesions.
